A new Vabysmo challenger? Innovent Biologics’ IBI324 just made the retinal drug race more interesting

Innovent Biologics (HKEX: 01801) said partner Ollin Biosciences had reported final 20-week data from the Phase 1b JADE study showing that OLN324, also known as IBI324, delivered stronger anatomic outcomes in diabetic macular edema and encouraging durability and vision trends against Roche’s faricimab, sold as Vabysmo. The result matters because the comparison was not against a weak incumbent but against one of the most commercially important retinal therapies in the market. Innovent and Ollin now plan to move OLN324 into global Phase 3 studies in both diabetic macular edema and wet age-related macular degeneration during 2026. For Innovent, that turns ophthalmology from an interesting side bet into a potential global value-creation engine if the Phase 3 package holds together.

Why does the latest IBI324 versus Vabysmo dataset matter more than a routine biotech update?

This is not just another small early-stage dataset dressed up in conference glitter. OLN324 was tested head-to-head against faricimab, which is already an established bispecific therapy in retinal disease and a major commercial asset for Roche. In the final 20-week readout, diabetic macular edema patients treated with OLN324 continued to show greater retinal drying, numerically stronger sustained vision gains, and fewer retreatments than the faricimab arm. In wet age-related macular degeneration, retinal drying appeared comparable overall, but OLN324 showed numerically greater vision gains and stronger pigment epithelial detachment flattening, which is one of the trickier anatomical problems in real-world disease control.

That matters because retinal drug competition is no longer just about matching vision gains over short windows. Physicians and payers increasingly care about durability, retreatment burden, and whether a therapy can improve difficult anatomical features without creating new safety headaches. OLN324’s claim to differentiation rests on being a smaller-format, higher-potency VEGF/Ang2 bispecific antibody with a higher molar dose than faricimab. If that translates into better disease control with fewer injections over time, Innovent and Ollin are not merely chasing incumbents. They are trying to redefine what the next commercial benchmark in retina could look like.

Could IBI324 give Innovent Biologics a more credible global ophthalmology franchise than investors expected?

Innovent has already been telling investors that it wants to evolve beyond its China biotech identity and build a broader multi-asset innovation platform. Its March 2026 annual results presentation highlighted ophthalmology as one of its key disease areas alongside oncology, cardiovascular and metabolic disease, and autoimmune disorders. IBI324 now looks like one of the cleaner examples of that ambition because retinal disease offers large global markets, repeat-use economics, and a more visible path to international partnering or commercialization than some earlier-stage assets in other categories.

The attraction is obvious. Roche’s Vabysmo generated CHF 4.1 billion in 2025 sales, showing that the wet age-related macular degeneration and diabetic macular edema markets remain large enough to reward meaningful clinical differentiation. In other words, this is not a science fair project. It is a shot at a market that has already proved it can mint multi-billion-dollar brands if the data support broader adoption. That makes OLN324 strategically relevant in a way many mid-stage biotech candidates never become. Retina, unlike some specialty niches, offers both scientific prestige and serious commercial scale.

What do the latest stock signals say about how the market is viewing Innovent Biologics right now?

Innovent Biologics shares were quoted around HK$86.1 on March 30, 2026, according to Hong Kong Exchanges and Clearing data, with a 52-week range of HK$36.6 to HK$109.1. Other market data pages around the same period also placed the stock in the mid-HK$80s, indicating that investors have already rerated the company substantially from its 52-week low even before any Phase 3 readout for IBI324. That suggests the market is not ignoring Innovent’s pipeline, but it also means some optimism may already be priced in. The stock is no longer being valued like a forgotten platform story sitting in the bargain bin with a handwritten “please take me” sign.

The key sentiment question is whether investors view IBI324 as incremental pipeline support or as a genuine global franchise candidate. If it is the former, the data are helpful but not transformative. If it is the latter, then the upcoming Phase 3 design, geographic recruitment footprint, regulatory interactions, and eventual partnering or commercialization strategy will matter far more than the current headline. Early efficacy and safety are important, but ophthalmology investors have seen enough promising mid-stage stories to know that the real valuation jump usually comes when a company proves it can replicate performance in larger, better-scrutinized studies.

Why might pigment epithelial detachment data become a bigger commercial talking point in wet AMD?

One of the more interesting parts of the release was the emphasis on pigment epithelial detachment, or PED, flattening in wet age-related macular degeneration. Innovent and Ollin said newly available pre-specified data showed faster and roughly 50% greater reductions in PED thickness at Week 12 for OLN324 4 mg versus faricimab, with more durable improvements through Week 20. Persistent PEDs are clinically important because they are associated with fibrosis and late vision loss, meaning this is not a cosmetic OCT story. If physicians become convinced that OLN324 can more effectively manage PEDs while preserving a clean safety profile, that could become a meaningful adoption lever in a crowded treatment landscape.

Commercially, this could matter because differentiation in retina often gets compressed into simplified talking points: how well does it dry the retina, how long does it last, and does it create inflammation risk. A therapy that adds stronger PED control to that conversation may gain traction among retina specialists looking for reasons to switch difficult patients or start new ones on a different protocol. That does not guarantee dominance, but it can help create the kind of practical clinical narrative that sales teams and medical affairs groups actually need.

What execution risks could still derail IBI324 even after encouraging head-to-head data?

The first obvious risk is scale. JADE enrolled 164 United States patients, which is meaningful for a Phase 1b head-to-head study but nowhere near enough to settle the commercial debate. Phase 3 studies in retina are larger, more expensive, more operationally complex, and far less forgiving if dosing schedules, retreatment rules, or subgroup responses become messy. What looks differentiated in a smaller trial can suddenly look merely interesting when tested across a broader global population.

The second risk is comparator pressure. Roche is not standing still with Vabysmo, which continues to generate data supporting efficacy, safety, durability, and additional labeled use in retinal disease. That means Innovent and Ollin will be trying to take share from an incumbent that already has physician familiarity, regulatory reach, and commercial infrastructure. Beating or matching an established therapy scientifically is hard enough. Beating it in the market is a second exam that comes with trickier questions and no partial credit.

The third risk is strategic execution across geographies. Ollin said planned Phase 3 studies are expected to recruit across North America, South America, Europe, and Japan, with active planning to include China and South Korea subject to regulatory communications. That ambition is encouraging, but it also raises the usual multinational trial questions around site consistency, regulatory alignment, enrollment speed, and eventual commercialization rights. A global program expands the opportunity set, but it also expands the list of things that can go wrong.

What happens next if Innovent Biologics can successfully carry IBI324 through Phase 3?

If Phase 3 confirms the current differentiation story, Innovent gains more than a promising asset. It gains proof that its discovery and partnership model can produce globally relevant specialty medicines beyond its more established therapeutic franchises. That would improve how investors think about the company’s platform quality, not just the standalone value of one ophthalmology drug. It could also open the door to stronger ex-China partnering leverage, better economics in future collaborations, and a more diversified long-term revenue narrative.

If Phase 3 disappoints, the damage is not existential given the breadth of Innovent’s broader pipeline, but it would weaken the argument that the company can build a meaningful global ophthalmology platform. In that scenario, IBI324 would shift from potential franchise asset to a reminder that retina remains an unforgiving market where incremental benefits are not always enough. For now, though, Innovent has done the one thing development-stage biotechs must do before the market takes them seriously. It has made the next study matter.

What are the key takeaways on what IBI324 means for Innovent Biologics, Roche, and the retinal disease market?

• Innovent Biologics has moved IBI324 from pipeline curiosity to a clinically relevant retinal challenger with global Phase 3 ambitions.
• Head-to-head data against faricimab give the asset more credibility than single-arm or placebo-controlled results would have.
• The strongest commercial angle may be the combined pitch of retinal drying, durability, and difficult-anatomy control rather than a single efficacy endpoint.
• Diabetic macular edema appears to be the cleaner near-term differentiation story, while wet age-related macular degeneration remains promising but more competitive.
• Roche’s Vabysmo remains a formidable incumbent with multi-billion-franc sales and established global positioning.
• For Innovent Biologics investors, the bigger thesis is platform validation and global franchise potential, not just one positive readout.
• The stock’s rebound from its 52-week low suggests market confidence has improved, but it also raises the bar for future execution.
• Phase 3 design quality, retreatment logic, and geographic execution will be more important than headline enthusiasm from a Phase 1b study.
• If PED control becomes a clinically meaningful commercial message, IBI324 could carve out a differentiated place in retina rather than compete only on parity.
• The retinal therapy market still rewards real innovation, but it punishes overpromising with impressive efficiency.